Frontlight ResearchEarly access
Acute myeloid leukaemia trials in Hungary
7 of 7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleStudies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Where
- Budapest IX, Debrecen, Győr, Kaposvár, Nyíregyháza
- Age
- 18 years and over
- People
- 1,300 worldwide
- Run by
- Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00 - Phase 3Taking peopleA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Where
- Budapest, Debrecen, Győr, Pécs, Szeged
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00 - Phase 3Taking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Budapest VIII, Debrecen, Győr, Szekszárd
- Age
- 12 years and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - Phase 2/3Taking peopleA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Where
- Budapest VIII, Debrecen, Győr, Szeged
- Age
- 18 years and over
- People
- 316 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00 - Phase 2Taking peopleA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Debrecen
- Age
- 18 years and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - Phase 1Not yet taking people in HungaryA Study to Assess Adverse Events and How Pivekimab Sunirine Moves Through the Body of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Where
- Budapest
- Age
- Up to 17 years
- People
- 18 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2024-520125-36-00 - Phase 3CompletedAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
- Where
- Budapest VIII, Debrecen, Pécs, Szeged
- Age
- 18 years and over
- People
- 245 worldwide
- Run by
- Servier Affaires Médicales
See details and how to joinNCT05907057 · EU 2022-501709-11-00